First Clinical Study on Long-Acting Growth Hormone Therapy in Children with Turner Sydrome
Horm Metab Res 2022; 54: 389-395 DOI: 10.1055/a-1842-0724Study on long-acting growth hormone (LAGH) therapy in Turner syndrome (TS) is a
2-year retrospective study including patients diagnosed with TS from
2018–2021. Patients were divided into four groups: Group 1 to 4 were low
dose (0.1 mg/kg/ w), high-dose
(0.2 mg/kg/w) LAGH, daily GH
(0.38 mg/kg/w), and untreated control. The efficacy and
safety data were analyzed. Seventy-five TS cases with the age 7.9±2.9
years and the bone age 6.8±2.8 years were recruited. In year 1: The
change of height standard deviation score (ΔHtSDS) and height velocity
(HV) in Group 2 were comparable to Group 3, both two groups were higher than
Group 1. ΔHtSDS and HV in all GH treatment group were higher than
untreated group. IGF1 increased in all treatment groups, only 4 cases had
IGF1>3 SD. In year 2: ΔHtSDS and HV in Group 2 and 3 were
comparable. Five cases had IGF1>3 SD. Correlation analysis for LAGH
efficacy at year 1 indicated that baseline variables correlated with
ΔHtSDS include: GH dose, CA (chronological age), and bone age (BA). The
HV was positively correlated with baseline GH dose, HtSDS, IGF-1SDS and
negatively correlated with baseline CA, BA, and BMI. No GH-related serious
adverse effects were observed. The high-dose LAGH treatment in TS...
Source: Hormone and Metabolic Research - Category: Endocrinology Authors: Gao, Xinying Chen, Jiajia Cao, Bingyan Dou, Xinyu Peng, Yaguang Su, Chang Qin, Miao Wei, Liya Fan, Lijun Zhang, Beibei Gong, Chunxiu Tags: Original Article: Endocrine Care Source Type: research